about
Role of the gastroenterologist in managing obesityPrinciples and pitfalls in the differential diagnosis and management of childhood obesitiesNaltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to dateMaternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthoodLipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP miceThe gastrin and cholecystokinin receptors mediated signaling network: a scaffold for data analysis and new hypotheses on regulatory mechanismsA peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeysPast and future corollaries of theories on causes of metabolic syndrome and obesity related co-morbidities part 2: a composite unifying theory review of human-specific co-adaptations to brain energy consumption.Phentermine and topiramate for the management of obesity: a review.Atherosclerosis and cardiac function assessment in low-density lipoprotein receptor-deficient mice undergoing body weight cyclingDo we need anti-obesity drugs?The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders.Peripheral targets in obesity treatment: a comprehensive update.The endocannabinoid system and appetite: relevance for food reward.Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway.Clinical trial success rates of anti-obesity agents: the importance of combination therapies.GLP-1 and Amylin in the Treatment of Obesity.An EASO position statement on multidisciplinary obesity management in adults.[Obesity--status quo and therapeutic approaches].Raspberry alleviates obesity-induced inflammation and insulin resistance in skeletal muscle through activation of AMP-activated protein kinase (AMPK) α1.
P2860
Q22241486-FAF918C4-9252-47AA-97B7-CA96473D8E85Q26820854-5E346D42-9B55-4365-937F-DB6A775CC83EQ27014110-D817637C-4D9C-48F0-A4C6-7EDB93053A0EQ28484561-71850F8C-BF88-484B-AE6D-2FEA73BB5CFFQ28732458-2A263A26-A031-4C37-8C59-56D4231984A1Q30982358-A27B1B9E-9EED-4339-97FF-C64A6BB6DE9AQ34231426-A7F9B6D2-E2B8-427C-A48B-C3067BDCFB3FQ35104485-032CB350-77C9-456A-B612-6184074D2A33Q36758207-2EF6A017-E048-4F90-A29F-ED6D83B78350Q36970065-B561AA83-931E-48FE-8C09-D6FEC2E2B715Q38071006-6EE9EFAB-B299-46CF-AFD1-9B52355AEF4AQ38115636-F77D0D8D-1D18-4F20-8D1D-84C905C54CEFQ38194649-48AB22EA-1D59-4F33-A556-D2A2A2DBAAECQ38220568-85B4AC33-1E99-4BA9-A2F3-D9A1D5C4B8E6Q38226897-09703E29-C248-482C-B97B-62528177B498Q38435784-D63BF38E-A3AB-49E1-81C8-3CD19E49323DQ38556863-7756E88E-E954-48E4-AF35-77C471113755Q38677851-75510BFA-952A-4CF0-918F-C5870B1502DFQ42221296-F0BDD946-E53C-4FFA-97C4-106C152B5D6CQ44479227-08BD347D-23D1-4BD7-B5B2-C8869D84470DQ55444813-348E3ACA-B377-4620-9327-E1C9C0FDF38E
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Current and future drug targets in weight management
@ast
Current and future drug targets in weight management
@en
type
label
Current and future drug targets in weight management
@ast
Current and future drug targets in weight management
@en
prefLabel
Current and future drug targets in weight management
@ast
Current and future drug targets in weight management
@en
P2860
P921
P1476
Current and future drug targets in weight management
@en
P2860
P304
P356
10.1007/S11095-010-0341-1
P577
2010-12-23T00:00:00Z
2011-08-01T00:00:00Z